CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer

Cancer Letters

Volumn 359, Issue 2, 2015, Pages 335-343

  Wei, Zhe Wei ^a,b   Xia, Guang Kai ^a,b   Wu, Ying ^a,b   Chen, Wei ^a,b   Xiang, Zhen ^a,b   Schwarz, Roderich E ^c   Brekken, Rolf A ^d   Awasthi, Niranjan ^c   He, Yu Long ^a,b   Zhang, Chang Hua ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; CXCL1; Gastric cancer; Prognosis; STAT3; VEGF

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CXCR2; CXCL1 CHEMOKINE; JANUS KINASE 2; LENTIVIRUS VECTOR; LIPOFECTAMINE; STAT3 PROTEIN; VASCULOTROPIN; CXCL1 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CAPILLARY DENSITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STOMACH CANCER; TUMOR GROWTH; TUMOR INVASION; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL MOTION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; PROTEIN PROCESSING; STOMACH TUMOR; TUMOR CELL LINE; TUMOR VOLUME; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CXCL1; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PROPORTIONAL HAZARDS MODELS; PROTEIN PROCESSING, POST-TRANSLATIONAL; STAT3 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS; TUMOR BURDEN; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84923114116     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.01.033     Document Type: Article

References (44)

1. Sasako M., Inoue M., Lin J.T., Khor C., Yang H.K., Ohtsu A. Gastric Cancer Working Group report. Jpn. J. Clin. Oncol 2010, 40(Suppl. 1):i28-i37.
2. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin 2011, 61:69-90.
3. Zhang C.H., Zhan W.H., He Y.L., Chen C.Q., Huang M.J., Cai S.R. Spleen preservation in radical surgery for gastric cardia cancer. Ann. Surg. Oncol 2007, 14:1312-1319.
4. Schwarz R.E., Zagala-Nevarez K. Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapy. Ann. Surg. Oncol 2002, 9:394-400.
5. Zhang C., Awasthi N., Schwarz M.A., Schwarz R.E. Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancer. J. Surg. Res 2013, 182:227-234.
6. Zhang C., He Y., Schwarz R.E., Smith D.D., Wang L., Liu F., et al. Evaluation of para-aortic nodal dissection for locoregionally advanced gastric cancer with 1-3 involved para-aortic nodes. Chin. Med. J. (Engl.) 2014, 127:435-441.
7. Xu J., Zhang C., He Y., Wu H., Wang Z., Song W., et al. Lymphatic endothelial cell-secreted CXCL1 stimulates lymphangiogenesis and metastasis of gastric cancer. Int. J. Cancer 2012, 130:787-797.
8. Wang D., Yang W., Du J., Devalaraja M.N., Liang P., Matsumoto K., et al. MGSA/GRO-mediated melanocyte transformation involves induction of Ras expression. Oncogene 2000, 19:4647-4659.
9. Yang G., Rosen D.G., Zhang Z., Bast R.C., Mills G.B., Colacino J.A., et al. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:16472-16477.
10. Cheng W.L., Wang C.S., Huang Y.H., Tsai M.M., Liang Y., Lin K.H. Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer. Ann. Oncol 2011, 22:2267-2276.
11. Katoh H., Wang D., Daikoku T., Sun H., Dey S.K., Dubois R.N. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 2013, 24:631-644.
12. Ogata H., Sekikawa A., Yamagishi H., Ichikawa K., Tomita S., Imura J., et al. GROalpha promotes invasion of colorectal cancer cells. Oncol. Rep 2010, 24:1479-1486.
13. Dong Y.L., Kabir S.M., Lee E.S., Son D.S. CXCR2-driven ovarian cancer progression involves upregulation of proinflammatory chemokines by potentiating NF-kappaB activation via EGFR-transactivated Akt signaling. PLoS ONE 2013, 8:e83789.
14. Ijichi H., Chytil A., Gorska A.E., Aakre M.E., Bierie B., Tada M., et al. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J. Clin. Invest 2011, 121:4106-4117.
15. Goto F., Goto K., Weindel K., Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab. Invest 1993, 69:508-517.
16. Quintas-Cardama A., Verstovsek S. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin. Cancer Res 2013, 19:1933-1940.
17. Van de Bor V., Zimniak G., Cerezo D., Schaub S., Noselli S. Asymmetric localisation of cytokine mRNA is essential for JAK/STAT activation during cell invasiveness. Development 2011, 138:1383-1393.
18. Niu G., Wright K.L., Huang M., Song L., Haura E., Turkson J., et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21:2000-2008.
19. Zhu B.H., Chen H.Y., Zhan W.H., Wang C.Y., Cai S.R., Wang Z., et al. Epigallocatechin-3-gallate inhibits VEGF expression induced by IL-6 via Stat3 in gastric cancer. World J. Gastroenterol 2011, 17:2315-2325.
20. Gong W., Wang L., Yao J.C., Ajani J.A., Wei D., Aldape K.D., et al. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin. Cancer Res 2005, 11:1386-1393.
21. Huang W., Yu L.F., Zhong J., Wu W., Zhu J.Y., Jiang F.X., et al. Stat3 is involved in angiotensin II-induced expression of MMP2 in gastric cancer cells. Dig. Dis. Sci 2009, 54:2056-2062.
22. Panopoulos A.D., Zhang L., Snow J.W., Jones D.M., Smith A.M., El Kasmi K.C., et al. STAT3 governs distinct pathways in emergency granulopoiesis and mature neutrophils. Blood 2006, 108:3682-3690.
23. Edge S.B., Byrd D.R., Compton C.C., et al. AJCC Cancer Staging Manual 2010, Springer-Verlag, New York. seventh ed.
24. Japanese Gastric Cancer Association Japanese classification of gastric carcinoma - 2nd English edition. Gastric Cancer 1998, 1:10-24.
25. Wang Z., He Y.L., Cai S.R., Zhan W.H., Li Z.R., Zhu B.H., et al. Expression and prognostic impact of PRL-3 in lymph node metastasis of gastric cancer: its molecular mechanism was investigated using artificial microRNA interference. Int. J. Cancer 2008, 123:1439-1447.
26. Nenutil R., Smardova J., Pavlova S., Hanzelkova Z., Muller P., Fabian P., et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J. Pathol 2005, 207:251-259.
27. Awasthi N., Zhang C., Ruan W., Schwarz M.A., Schwarz R.E. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol. Cancer Ther 2012, 11:2644-2653.
28. Dhawan P., Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J. Leukoc. Biol 2002, 72:9-18.
29. Roussos E.T., Condeelis J.S., Patsialou A. Chemotaxis in cancer. Nat. Rev. Cancer 2011, 11:573-587.
30. Wang D., Wang H., Brown J., Daikoku T., Ning W., Shi Q., et al. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J. Exp. Med 2006, 203:941-951.
31. Jablonska J., Wu C.F., Andzinski L., Leschner S., Weiss S. CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-beta. Int. J. Cancer 2014, 134:1346-1358.
32. Miyake M., Goodison S., Urquidi V., Gomes Giacoia E., Rosser C.J. Expression of CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor and the ERK1/2 and EGF pathways. Lab. Invest 2013, 93:768-778.
33. Zhao R., Liu X.Q., Wu X.P., Liu Y.F., Zhang Z.Y., Yang G.Y., et al. Vascular endothelial growth factor (VEGF) enhances gastric carcinoma invasiveness via integrin alpha(v)beta6. Cancer Lett 2010, 287:150-156.
34. Nakanishi R., Oka N., Nakatsuji H., Koizumi T., Sakaki M., Takahashi M., et al. Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer. Urol. Int 2009, 83:98-106.
35. Lieto E., Ferraraccio F., Orditura M., Castellano P., Mura A.L., Pinto M., et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann. Surg. Oncol 2008, 15:69-79.
36. Burger M., Hartmann T., Burger J.A., Schraufstatter I. KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway. Oncogene 2005, 24:2067-2075.
37. Kim D.Y., Cha S.T., Ahn D.H., Kang H.Y., Kwon C.I., Ko K.H., et al. STAT3 expression in gastric cancer indicates a poor prognosis. J. Gastroenterol. Hepatol 2009, 24:646-651.
38. Xiong H., Du W., Wang J.L., Wang Y.C., Tang J.T., Hong J., et al. Constitutive activation of STAT3 is predictive of poor prognosis in human gastric cancer. J. Mol. Med. (Berl.) 2012, 90:1037-1046.
39. Deng J.Y., Sun D., Liu X.Y., Pan Y., Liang H. STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer. World J. Gastroenterol 2010, 16:5380-5387.
40. Acharyya S., Oskarsson T., Vanharanta S., Malladi S., Kim J., Morris P.G., et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012, 150:165-178.
41. Sharma B., Nawandar D.M., Nannuru K.C., Varney M.L., Singh R.K. Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis, and lung metastasis. Mol. Cancer Ther 2013, 12:799-808.
42. Ohtsu A., Shah M.A., Van Cutsem E., Rha S.Y., Sawaki A., Park S.R., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J. Clin. Oncol 2011, 29:3968-3976.
43. Okines A.F., Langley R.E., Thompson L.C., Stenning S.P., Stevenson L., Falk S., et al. Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. Ann. Oncol 2013, 24:702-709.
44. Aguilera K.Y., Rivera L.B., Hur H., Carbon J.G., Toombs J.E., Goldstein C.D., et al. Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma. Cancer Res 2014, 74:1032-1044.